Profile data is unavailable for this security.
About the company
Delta-Fly Pharma, Inc. is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.
- Revenue in JPY (TTM)0.00
- Net income in JPY-1.66bn
- Incorporated2010
- Employees13.00
- LocationDelta-Fly Pharma Inc37-5, Nishikino, Miyajima, Kawauchi-choTOKUSHIMA-SHI 771-0116JapanJPN
- Phone+81 362311278
- Websitehttps://www.delta-flypharma.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Delta-Fly Pharma Inc | 0.00 | -1.66bn | 2.72bn | 13.00 | -- | 13.13 | -- | -- | -153.26 | -153.26 | 0.00 | 17.06 | 0.00 | -- | -- | 0.00 | -288.88 | -88.06 | -369.76 | -97.02 | -- | -- | -- | -1,051.54 | -- | -- | 0.00 | -- | -- | -- | -20.41 | -- | -61.24 | -- |
| Perseus Proteomics Inc | 140.41m | -758.12m | 3.39bn | 32.00 | -- | 3.83 | -- | 24.16 | -51.42 | -51.42 | 9.52 | 59.98 | 0.0846 | 3.48 | 7.92 | 4,387,750.00 | -45.69 | -38.61 | -48.88 | -40.75 | 86.21 | 90.16 | -539.94 | -837.30 | 12.86 | -- | 0.00 | -- | 19.89 | 7.02 | 18.08 | -- | 95.88 | -- |
| Muromachi Chemicals Inc | 7.37bn | 364.59m | 4.94bn | 203.00 | 13.47 | 1.83 | 9.14 | 0.6707 | 89.59 | 89.59 | 1,819.39 | 658.42 | 1.23 | 3.81 | 5.84 | 36,304,700.00 | 6.09 | 5.99 | 8.66 | 10.36 | 29.85 | 29.90 | 4.95 | 4.89 | 1.76 | 18.37 | 0.4769 | 26.50 | 4.46 | 4.73 | -26.93 | 50.19 | 32.64 | -- |
| Symbio Pharmaceuticals Ltd | 1.31bn | -4.78bn | 5.64bn | 108.00 | -- | 4.11 | -- | 4.31 | -95.49 | -95.49 | 26.04 | 21.39 | 0.296 | 1.37 | 3.83 | -- | -108.11 | -19.84 | -140.91 | -24.15 | 72.45 | 74.71 | -365.25 | -26.66 | 2.74 | -44.43 | 0.6092 | -- | -46.69 | -15.23 | -24.59 | -- | -11.15 | -- |
| MEDRx Co Ltd | 128.08m | -937.37m | 5.94bn | 22.00 | -- | 2.90 | -- | 46.35 | -18.25 | -18.25 | 2.38 | 34.52 | 0.0578 | 0.0891 | 4.48 | -- | -42.29 | -48.18 | -44.11 | -51.18 | 99.06 | 98.18 | -731.84 | -1,002.97 | 23.40 | -319.43 | -- | -- | -50.34 | 2.16 | -16.19 | -- | 16.00 | -- |
| Kohjin Bio Co Ltd | 5.07bn | 557.40m | 6.13bn | 167.00 | 11.00 | 1.04 | 6.49 | 1.21 | 109.06 | 109.06 | 992.83 | 1,157.47 | 0.5768 | 3.51 | 4.58 | 30,386,960.00 | 6.34 | -- | 8.73 | -- | 43.01 | -- | 10.98 | -- | 1.49 | -- | 0.2443 | -- | 9.14 | -- | 106.44 | -- | -- | -- |
| Nippon Chemiphar Co Ltd | 32.52bn | 545.00m | 7.62bn | 855.00 | 11.85 | 0.337 | 3.72 | 0.2344 | 151.00 | 151.00 | 9,009.80 | 5,309.46 | 0.6233 | 1.98 | 2.75 | 38,035,090.00 | 1.04 | 0.6794 | 1.44 | 0.9686 | 26.19 | 28.43 | 1.68 | 1.04 | 1.34 | -- | 0.4785 | 55.16 | 5.93 | 0.5075 | 263.33 | -7.58 | 32.85 | 0.00 |
| CellSource Co Ltd | 3.71bn | 10.66m | 7.77bn | 148.00 | 783.47 | 1.29 | 37.20 | 2.09 | 0.5003 | 0.5003 | 186.84 | 303.58 | 0.5265 | 5.91 | 11.31 | 25,077,400.00 | 0.1512 | 10.68 | 0.1613 | 11.89 | 56.24 | 64.88 | 0.2872 | 14.37 | 11.79 | 16.09 | 0.0093 | 20.88 | -14.78 | 14.87 | -95.52 | -47.76 | 8.90 | -- |
| COSMO BIO COMPANY, LIMITED | 10.77bn | 337.00m | 7.90bn | 174.00 | 22.10 | 0.7912 | 15.78 | 0.7342 | 59.14 | 59.14 | 1,893.02 | 1,651.94 | 0.883 | 6.53 | 3.57 | -- | 2.74 | 4.41 | 3.24 | 5.24 | 34.39 | 35.52 | 3.10 | 4.88 | 4.46 | -- | 0.002 | 50.68 | 7.26 | 5.88 | 28.63 | -12.94 | 34.02 | 8.02 |
| Solasia Pharma KK | 429.00m | -876.00m | 8.08bn | 23.00 | -- | 4.51 | -- | 18.83 | -3.79 | -3.79 | 1.81 | 6.65 | 0.2447 | 1.84 | 2.13 | -- | -49.96 | -64.76 | -58.36 | -79.60 | 48.48 | 58.61 | -204.20 | -297.25 | 5.70 | -61.50 | 0.0514 | -- | 35.76 | -1.13 | 54.87 | -- | -- | -- |
| K Pharma Inc | 0.00 | -993.23m | 8.46bn | 17.00 | -- | 6.69 | -- | -- | -85.59 | -85.59 | 0.00 | 109.00 | 0.00 | 0.00 | -- | -- | -37.53 | -- | -38.74 | -- | -- | -- | -- | -- | 28.29 | -1,982.81 | 0.5424 | -- | -- | -- | -17.34 | -- | -- | -- |
| Wakamoto Pharmaceutical Co Ltd | 9.29bn | 298.60m | 11.11bn | 286.00 | 37.08 | 0.9157 | 15.00 | 1.20 | 8.60 | 8.60 | 267.77 | 348.39 | 0.6006 | 1.62 | 3.06 | 32,493,160.00 | 1.93 | -0.0678 | 2.22 | -0.0781 | 47.70 | 48.65 | 3.21 | -0.1246 | 2.42 | -- | 0.0082 | -- | 0.6595 | -6.53 | -40.86 | -- | 21.87 | -- |
Data as of Feb 17 2026. Currency figures normalised to Delta-Fly Pharma Inc's reporting currency: Japanese Yen JPY
2.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Macquarie Bank Ltd. (Private Banking)as of 02 Feb 2026 | 313.10k | 2.58% |
Data from 10 Feb 2026 - 10 Feb 2026Source: FactSet Research Systems Inc.
